RxDoctor Payments Data

Amy Miller, MD

Family Medicine · Silver Spring, MDNPI 1811962095

Payments from drug & device makers

$2,643in general payments, 2019–2025

Across 166 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$166
  • Amgen$141
  • Avanir Pharmaceuticals, Inc.$138
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$121
  • Orthofix Medical, Inc.$119
  • plus $900 from 22 others

What the payments were for

  • Speaking & faculty fees$793%
  • Food & beverage$2,56597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,643 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$7,691
Medicare patients
47
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$7,294
Cromolyn Sodium18$5,333
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,404
Pyridostigmine Bromide33$1,492
Clemastine Fumarate11$1,276
Hydroxychloroquine Sulfate12$836
Famotidine51$704
Duloxetine Hcl20$576
Oxcarbazepine12$569
Omeprazole32$501
Prazosin Hcl11$474
Levothyroxine Sodium60$472
Hydroxyzine Hcl28$403
Amitriptyline Hcl19$332
Celecoxib13$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieArmour Thyroid$1,058$30313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →